Table 2.
Univariate regression and multivariate Cox regression analysis for those >65 years with diabetes with tuberculosis.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| RR | 95% CI | p Value | ARR | 95% CI | p Value | |
| Gout | 0.92 | 0.49–1.73 | 0.8192 | 0.93 | 0.48–1.77 | 0.8192 |
| Hypertension | 0.90 | 0.68–1.18 | 0.4281 | 0.90 | 0.66–1.22 | 0.4837 |
| Hyperlipidemia | 0.47 | 0.25–0.88 | 0.0179 | 0.57 | 0.30–1.09 | 0.0867 |
| Age (mean ± SD) | 1.04 | 1.03–1.06 | <0.0001 | 1.04 | 1.02–1.06 | <0.0001 |
| Sex (Male) | 2.02 | 1.64–2.49 | <0.0001 | 1.84 | 1.46–2.31 | <0.0001 |
| Income category monthly income >NT $20,000 | 1.40 | 0.89–2.20 | 0.1429 | 1.33 | 0.84–2.09 | 0.2206 |
| Northern cities | 1.05 | 0.67–1.64 | 0.8336 | 1.01 | 0.64–1.57 | 0.9828 |
| Southern cities | 0.96 | 0.54–1.74 | 0.9027 | 0.89 | 0.50–1.61 | 0.7038 |
| Northern counties | 0.94 | 0.71–1.24 | 0.6676 | 0.94 | 0.71–1.24 | 0.6480 |
| Southern counties | 1.46 | 1.09–1.94 | 0.011 | 1.39 | 1.03–1.86 | 0.0288 |
| Asthma | 2.07 | 1.39–3.09 | 0.0004 | 1.83 | 1.17–2.86 | 0.0080 |
| COPD | 1.63 | 1.18–2.26 | 0.0031 | 1.34 | 0.92–1.95 | 0.1260 |
| AIDS | - | - | - | - | - | - |
| Connective tissue disease | 0.52 | 0.13–2.08 | 0.3533 | 0.53 | 0.13–2.15 | 0.3732 |
| End stage renal disease | 0.62 | 0.16–2.50 | 0.5042 | 0.63 | 0.15–2.50 | 0.5150 |
| Heart failure | 0.98 | 0.54–1.78 | 0.9441 | 0.72 | 0.38–1.35 | 0.3035 |
| Other cardiovascular disease | 1.31 | 0.91–1.91 | 0.1538 | 1.33 | 0.89–1.99 | 0.1652 |
| Sulfonylureas | 1.17 | 0.90–1.53 | 0.2460 | 1.30 | 0.99–1.78 | 0.0624 |
| Metformin | 0.93 | 0.76–1.16 | 0.5303 | 0.93 | 0.73–1.17 | 0.5209 |
| Acarbose | 1.31 | 1.04–1.66 | 0.0215 | 1.29 | 1.00–1.66 | 0.0493 |
| Thiazolidinediones | 0.91 | 0.65–1.27 | 0.5740 | 0.88 | 0.62–1.25 | 0.4842 |
| Meglitinides | 1.50 | 1.19–1.88 | 0.0005 | 1.45 | 1.14–1.85 | 0.0026 |
| Insulin | 1.50 | 1.05–1.93 | 0.0246 | 1.42 | 1.04–1.96 | 0.0286 |
| ACEI | 1.08 | 0.88–1.33 | 0.4463 | 1.14 | 0.92–1.43 | 0.2380 |
| ARB | 0.80 | 0.66–0.99 | 0.0362 | 0.85 | 0.68–1.07 | 0.1748 |
| Beta-blockers | 0.70 | 0.57–0.86 | 0.0008 | 0.72 | 0.58–0.91 | 0.0048 |
| Calcium channel blockers | 0.76 | 0.60–0.96 | 0.0199 | 0.76 | 0.58–0.98 | 0.0374 |
| Diuretics | 1.35 | 1.09–1.66 | 0.0053 | 1.41 | 1.13–1.77 | 0.0028 |
| Hydralazine plus nitrate | 1.09 | 0.27–4.37 | 0.9013 | 1.23 | 0.31–4.97 | 0.7703 |
| All nitrates | - | - | - | - | - | - |
| Isosorbide | 1.24 | 0.98–1.59 | 0.0791 | 1.32 | 1.02–1.71 | 0.0323 |
| Other anti-hypertensives | 1.42 | 1.16–1.74 | 0.0008 | 1.09 | 0.87–1.37 | 0.4617 |
| Statins | 0.66 | 0.53–0.83 | 0.0004 | 0.76 | 0.60–0.97 | 0.0291 |
| Other anti-hyperlipidemia agents | 0.77 | 0.58–1.03 | 0.0775 | 0.93 | 0.69–1.25 | 0.6123 |
ARR = absolute risk reduction; ACEI = angiotensin-converting-enzyme inhibitor; AIDS = acquired immune deficiency syndrome; ARB = angiotensin II receptor blocker; CI = confidence interval; COPD = Chronic obstructive pulmonary disease; RR = risk reduction.